Please find enclosed the 2023 Annual Report for Exact Therapeutics.


For further information, please contact:

Per Walday 
CEO EXACT Therapeutics 
Email: per.walday@exact-tx.com 

John M. Edminson
CFO EXACT Therapeutics
Email: john.edminson@exact-tx.com

About EXACT-Tx: 
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to enable or significantly amplify the
clinical utility of a wide range of therapeutic agents across a multitude of
indications including within oncology (chemotherapy, immunotherapy) and brain
diseases. www.exact-tx.com 


About ACT® 
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
o ACT® is being tested in the clinic and has released positive interim data. It
is supported by a strong and broad preclinical package demonstrating therapeutic
enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as
well as blood-brain barrier penetration. 
o Initial focus of the Company is oncology. The ACT® platform has potential
across many therapeutic areas (including CNS, immunotherapy) and product
classes. 

Forward looking statements: This announcement and any materials distributed in
connection with this announcement may contain certain forward-looking
statements. By their nature, forward-looking statements involve risk and
uncertainty because they reflect the Company's current expectations and
assumptions as to future events and circumstances that may not prove accurate. A
number of material factors could cause actual results and developments to differ
materially from those expressed or implied by this forward-looking statement.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.